First FDA-approved plasmid DNA-based immunotherapy developed by INOVIO and manufactured by Richter BioLogics – the exclusive API Manufacturing Partner

Milestone achieved

A zero-finding FDA inspection means a manufacturer’s systems, batch records, and processes met the highest regulatory standard with no observations raised.

For biologics and gene therapy partners, this translates directly into reduced timeline risk, dependable supply continuity, and the confidence to focus on advancing their therapy rather than managing manufacturing uncertainty.

We recently experienced exactly this result supporting our longtime partner INOVIO through FDA approval of its VOCERYQ™, the first FDA-approved plasmid DNA-based immunotherapy.

It’s the clearest signal available that a manufacturing partner’s systems, discipline, and culture of quality can be trusted with a therapy’s commercial future.

Congratulations to INOVIO on the FDA Approval of VOCERYQ™

The FDA granted accelerated approval for VOCERYQ™ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd), developed by INOVIO. This approval marks a defining moment, not just for INOVIO, but for the plasmid DNA therapeutic field, since VOCERYQ™ is the first FDA-approved plasmid DNA-based immunotherapy to reach patients.

With this approval, INOVIO has also started a transition to a commercial-stage company, a milestone that reflects years of scientific development, clinical execution, and manufacturing readiness working in lockstep.

As the exclusive CDMO partner responsible for manufacturing the plasmid DNA (pDNA) active pharmaceutical ingredient (API), our organization played a direct role in bringing this therapy to commercial market readiness. That responsibility carried weight. Every batch, every quality check, and every regulatory submission had to meet the standard required to support a first-in-class therapy.

Robert J. Juba Jr., Senior Vice President, Biological Manufacturing & Clinical Supply Management at INOVIO captured the significance of this collaboration directly: „This milestone would not have been possible without partners like Richter. Thank you for your collaboration and support for this program along the way.“

That statement reflects what a true manufacturing partnership looks like in practice: sustained collaboration through every stage of development, scale-up, and regulatory scrutiny.

Why Does a Zero-Finding FDA Inspection Matter So Much for Biologics Programs?

Biotech sponsors often ask what a clean FDA inspection actually changes for their program. The answer comes down to three concrete outcomes.

It Means Reduced Risk

When a regulatory body examines every system and batch record without raising a single observation, a product’s timeline is protected from costly delays and remediation. For sponsors operating on tight clinical and commercial launch schedules, this is not a minor benefit. A single adverse finding can trigger corrective action plans, re-inspections, or production holds that ripple through an entire development program. Zero findings means none of that risk materializes.

It Means Reliability

A manufacturing partner that passes inspection without findings demonstrates that its quality systems function correctly every day, not just when regulators are watching. For sponsors managing multiple programs or coordinating global launches, that predictability is what keeps supply chains dependable.

It Means Confidence

Sponsors can focus on advancing their therapy, knowing the manufacturing side is held to the highest regulatory standard. This confidence extends beyond the sponsor’s internal teams. Investors, regulatory agencies, and ultimately patients all benefit when a therapy’s manufacturing foundation is demonstrably sound.

For partners who trust us with their biologics, a result like this is more than a credential. It is proof of the discipline applied on their behalf, every single day.

What Does This Milestone Reflect About Manufacturing Excellence?

The FDA approval of VOCERYQ™ reflects several dimensions of manufacturing performance at our sites that sponsors evaluating a CDMO should weigh carefully.

Highest quality standards

This achievement is evidenced by the successful FDA inspection at our manufacturing facility in May, conducted ahead of the approval, and the subsequent FDA approval itself. A regulatory inspection of this nature examines everything from facility controls to documentation practices, and passing without findings show that these systems hold up under direct scrutiny.

Reliable scale-up to commercial-scale production

Moving a therapy from clinical-scale manufacturing to full commercial-scale production is one of the most technically demanding transitions. Our teams demonstrated excellence at every stage of that scale-up, ensuring that process consistency and product quality were preserved as volumes increased.

Patient-centered impact

API production directly contributes to delivering this life-changing therapy to patients worldwide. That outcome is the reason manufacturing discipline matters in the first place. Every quality control step and every successful inspection ultimately connects back to patients waiting for access to new treatment options.

Why Choose a CDMO With a Track Record in Late-Stage and Commercial Manufacturing?

Choose a CDMO with demonstrated commercial-scale experience if your program depends on predictable regulatory outcomes and uninterrupted supply, since these later stages carry the highest stakes for both patients and sponsors.

A CDMO’s commercial readiness isn’t established through claims. It’s established through regulatory history: successful inspections, accelerated approvals supported by manufacturing data, and sustained partnerships that carry a program from clinical development through to market. The INOVIO collaboration demonstrates exactly this kind of track record advancing from late clinical to commercial-scale API manufacturing.

A Partnership Built on Discipline, Not Just Capability

This approval represents more than a regulatory and commercial achievement for INOVIO. It underlines an approach to manufacturing partnership defined by discipline, transparency, and sustained collaboration through every development milestone.

A sincere thank you is extended to INOVIO and to the full project team for an outstanding, collaborative partnership. Milestones like the approval of VOCERYQ™ don’t happen through manufacturing capability alone. They happen when a CDMO and sponsor commit to the same standard of excellence, inspection after inspection, batch after batch.

Our commitment remains simple: protect your product, uphold quality, and earn your trust with every batch.

Das könnte sie auch interessieren